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Summary
 
To assess the potency of low-affinity anti–red blood cell (RBC) autoantibodies in the induc-
tion of anemia, we generated an immunoglobulin (Ig)G2a class-switch variant of a 4C8 IgM
anti–mouse RBC autoantibody, and compared its pathogenic potential with that of its IgM
isotype and a high-affinity 34-3C IgG2a autoantibody. The RBC-binding activity of the 4C8
IgG2a variant was barely detectable, at least 1,000 times lower than that of its IgM isotype, hav-
ing a high-binding avidity, and that of the 34-3C IgG2a monoclonal antibody (mAb). This
low-affinity feature of the 4C8 mAb was consistent with the lack of detection of opsonized
RBCs in the circulating blood from the 4C8 IgG2a–injected mice. However, the 4C8 IgG2a
variant was highly pathogenic, as potent as its IgM isotype and the 34-3C IgG2a mAb, due to
its capacity to interact with Fc receptors involved in erythrophagocytosis. In addition, our results
indicated that the pentameric form of the low-affinity IgM isotype, by promoting the binding
and agglutination of RBCs, is critical for its pathogenic activity. Demonstration of the remark-
ably high pathogenic potency of low-affinity autoantibodies, if combined with appropriate heavy
chain effector functions, highlights the critical role of the Ig heavy chain constant regions, but the
relatively minor role of autoantigen-binding affinities, in autoimmune hemolytic anemia.
Key words: autoantibody • autoimmune hemolytic anemia • Fc receptor • Kupffer cell • 
knockout mouse
 
T
 
he pathogenesis of autoantibody-mediated cellular and
tissue lesions in autoimmune diseases is most straight-
forwardly attributable to the combined action of self-anti-
gen binding properties and effector functions associated
with the Fc regions of the different Ig isotypes, such as the
capacity to bind Fc receptors for IgG (Fc
 
g
 
R),
 
1
 
 activate
complement, and cause multivalence-induced agglutination.
This is best exemplified by remarkable differences among a
panel of Coombs’ anti-RBC monoclonal autoantibodies,
established from lupus-prone NZB mice, in their ability to
induce autoimmune hemolytic anemia (1–5).
It has been believed that the high-affinity binding of au-
toantibodies to self-antigens is likely to be critical for the
expression of their pathogenic activities in vivo. This notion
has been supported by the demonstration that the Ig genes
in a subset of autoantibody-producing B cells, which are
clonally expanded, are modified by somatic mutations, es-
pecially in their CDR3 (6, 7), and that the affinity matura-
tion of autoantibodies in association with IgM to IgG class
switching coincides with progression of the clinical devel-
opment of autoimmune diseases, most notably SLE (8, 9).
However, the affinity maturation of autoantibodies in par-
allel to Ig class switch and somatic hypermutations is not a
consistent observation. Analysis of clonally related anti-IgG2a
rheumatoid factors isolated from a lupus-prone MRL-
 
lpr/lpr
 
mouse has demonstrated only limited affinity maturation,
despite Ig isotype switching with extensive somatic muta-
tions (10). Most significantly, studies on a panel of anti-IgG2a
rheumatoid factor monoclonal autoantibodies disclosed that
even low-affinity autoantibodies are able to induce immune
complex–mediated vasculitis, with a cryoglobulin activity
uniquely associated with murine IgG3 isotype (11, 12).
Recent studies on anti–mouse RBC monoclonal auto-
antibodies revealed a major role of Fc
 
g
 
R-mediated erythro-
phagocytosis in the development of anemia induced by IgG
anti-RBC autoantibodies (13, 14). Thus, it can be specu-
lated that low-affinity anti-RBC autoantibodies of IgG iso-
types could become highly pathogenic, if combined with the
 
1
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capacity to interact with Fc
 
g
 
R expressed on phagocytic ef-
fector cells. To explore this possibility, we have generated
an IgG2a class-switch variant from an NZB-derived 4C8
IgM anti–mouse RBC monoclonal autoantibody (2). Since
it has been generally thought that the IgM antibody has a
low affinity, we should be able to study the pathogenic ac-
tivity of low-affinity anti-RBC autoantibody of IgG2a iso-
type capable of interacting with phagocytic Fc
 
g
 
R (13, 14).
In the present work, comparative analysis of the 4C8 IgG2a
variant with its IgM isotype and a high-affinity 34-3C IgG2a
anti–mouse RBC monoclonal autoantibody, established from
NZB mice (4), demonstrates that despite a low binding af-
finity, both 4C8 IgM and IgG2a isotypes are remarkably
pathogenic, because of the high-avidity binding capacity of
polyvalent IgM isotype or because of a high-affinity inter-
action of IgG2a isotype with Fc
 
g
 
R involved in erythro-
phagocytosis.
 
Materials and Methods
 
Mice.
 
BALB/c mice were purchased from Bomholtgard. Mice
deficient in FcR 
 
g
 
 chains (FcR
 
g
 
), which lack functional expression
of both Fc
 
g
 
R type I (Fc
 
g
 
RI) and type III (Fc
 
g
 
RIII), and wild-
type littermates were developed as described previously (15).
 
DNA Construction.
 
The VDJH4C8-C
 
g
 
2a plasmid containing
the complete 4C8 IgG heavy chain gene of the IgG2a isotype was
constructed using the following DNA fragments: the rearranged
VDJ region isolated from cDNA encoding the variable region of
the heavy chain of the 4C8 mAb (16), the promoter region isolated
from pSV-V
 
m
 
1 (17), the heavy chain enhancer region isolated
from pSVE2-neo (18), and the C
 
g
 
2a region derived from the ge-
nomic clone, pIgH10 (19).
 
mAbs.
 
Hybridomas secreting the 4C8 IgM and 34-3C IgG2a
anti–mouse RBC mAbs were derived from unmanipulated NZB
mice (2, 4). The 4C8 IgG2a class-switch variant was obtained by
transfecting 4C8 heavy chain loss mutant cells by electroporation
with the VDJH4C8-C
 
g
 
2a plasmid together with a pSVE2-neo
plasmid containing the neomycin-resistant gene. After selection for
resistance to neomycin and secretion of IgG antibodies, stable
transfected cells secreting the 4C8 IgG2a variant were cloned by
limiting dilutions. IgG2a anti-TNP (Hy1.2) and IgM anti-IgG2a
(6-19) mAbs were used as control. Rat anti–mouse 
 
k
 
 chain mAb
(H139.52.1.5) was provided by Dr. M. Pierres (Centre d’Immu-
nologie de Marseille-Luminy, Marseille, France [20]). IgG mAbs
were purified from culture supernatants by protein A column
chromatography. IgM mAbs were purified by euglobulin pre-
cipitation from culture supernatants concentrated by 50% saturated
ammonium sulfate precipitation, according to the method of Gar-
cia-Gonzales et al. (21). The purity of IgG and IgM was 
 
.
 
90% as
documented by SDS-PAGE.
 
Reverse Transcriptase PCR and cDNA Sequencing.
 
RNA was
prepared from 4C8 IgG2a–transfected cells by RNeasy Mini Kit
(Qiagen). The first strand of cDNA was synthesized with an
oligo(dT) primer and 5 
 
m
 
g of total RNA. For amplification with
 
Pfu
 
 DNA polymerase (Stratagene), the following primers were
used: 5
 
9
 
-untranslated VH primer (5
 
9
 
-CAGTTCTCTCTACAG-
TTA-3
 
9
 
) and C
 
g
 
2a-CH1 primer (5
 
9
 
-GCCAGTGGATAGAC-3
 
9
 
)
for the 4C8 heavy chain; 5
 
9
 
-untranslated V
 
k
 
 primer (5
 
9
 
-CAG-
GGGAAGCAAGATGG-3
 
9
 
) and C
 
k
 
 primer (5
 
9
 
-TGGATGGTG-
GGAAGATG-3
 
9
 
) for the 4C8 light chain. The nucleotide se-
quence corresponding to the variable region of the 4C8 heavy or
light chain was determined by the dideoxynucleotide chain ter-
minating method (22).
 
Anti–Mouse RBC Assays.
 
A flow cytometric assay was used
to detect anti–mouse RBC activities of purified mAbs. 50 
 
m
 
l of
various concentrations of purified mAbs was incubated with 20 
 
m
 
l
of 1% RBC suspension, prepared from BALB/c mice, in 1%
BSA-PBS for 30 min at 4
 
8
 
C. After washing three times with 1%
BSA-PBS, the RBCs were incubated with biotinylated rat anti–
mouse 
 
k
 
 chain mAb (H139.52.1.5), followed by PE-conjugated
streptavidin R (Caltag), and analyzed with a FACScan™ (Becton
Dickinson). The presence of opsonized RBCs in mice injected
with anti–mouse RBC mAb was detected by a similar flow cyto-
metric assay, using biotinylated rat anti–mouse 
 
k
 
 chain mAb. For
in vitro and in vivo bindings of anti–mouse RBC mAb on bio-
tinylated mouse RBCs, bound antibodies were revealed with PE-
labeled F(ab
 
9
 
)
 
2
 
 goat anti–mouse Ig conjugates (Jackson Immuno-
Research Labs). An indirect radioimmunoassay was also used to
detect anti–mouse RBC activities of mAbs, as described previ-
ously (4). In brief, 100 
 
m
 
l of various concentrations of purified
mAbs was incubated with 10 
 
m
 
l of 25% RBC suspension in 1%
BSA-PBS for 30 min at 4
 
8
 
C. After washing three times with 1%
BSA-PBS, the RBCs were incubated with 
 
125
 
I-labeled goat anti–
mouse Ig in 1% BSA-PBS. Results are expressed as the radioac-
tivity (in cpm) bound to RBCs. Complement-mediated lysis and
hemagglutination assays were as described previously (4).
 
Experimental Autoimmune Hemolytic Anemia.
 
Autoimmune
hemolytic anemia was induced by a single intraperitoneal injec-
tion of purified anti-RBC mAb into 2–3-mo-old mice. Blood
samples were collected into heparinized microhematocrit tubes and
centrifuged in a hematocentrifuge, and hematocrits (Ht) were di-
rectly determined after centrifugation, as described previously (4).
 
In Vivo Biotinylation of Mouse RBCs.
 
Mouse RBCs were bi-
otinylated in vivo by an intravenous infusion of 
 
N
 
-hydroxysuc-
cinimide biotin (NHS-biotin; Boehringer Mannheim), according
to the method described by Dale and Daniels (23). In brief, 2 mg
NHS-biotin was dissolved in 0.12 ml 
 
N,N
 
-dimethylacetamide
(Sigma Chemical Co.), incubated for 2 min in the dark at 37
 
8
 
C,
and added to 3.2 ml sterile saline. 500 
 
m
 
g of NHS-biotin was
then injected intravenously into mice. This in vivo biotinylation
procedure resulted in essentially all the RBCs being biotinylated,
as judged by staining with streptavidin Red 670 (GIBCO BRL)
24 h after the infusion of NHS-biotin.
 
Histological Studies.
 
Livers and spleens were obtained at autopsy,
processed for histological examination, and stained with hema-
toxylin and eosin (HE). The extent of in vivo RBC destruction
by Kupffer cell–mediated phagocytosis was revealed by colora-
tion of liver sections with Perls iron staining.
 
Results
 
Low-Affinity Binding to Mouse RBCs by the 4C8 IgG2a
Isotype-Switch Variant.
 
The strategy for generating the re-
combinant IgG2a isotype-switch variant was to clone the
heavy chain variable region (VH) gene from the 4C8 IgM
anti–mouse RBC hybridoma and to join this gene to the
already cloned mouse IgG2a heavy chain constant region
gene. The recombinant IgG2a isotype-switch variant was
then expressed in a heavy chain loss mutant of the 4C8
IgM hybridoma. Notably, the VH4C8 and V
 
k
 
4C8 se-
quences of the 4C8 heavy and light chain cDNA derived
from a reverse transcription PCR amplification of mRNA 
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isolated from the cells secreting 4C8 IgG2a switch variant
were identical to the originally published sequence (16).
The in vitro binding activity of the 4C8 IgG2a switch
variant, compared with its IgM isotype and the high-affin-
ity 34-3C IgG2a anti–mouse RBC mAb, was investigated
by flow cytometric analysis using a biotinylated rat anti–
mouse 
 
k
 
 chain mAb, followed by PE-conjugated streptavi-
din. Incubation of mouse RBCs with 0.1 ng of the 4C8
IgM or 34-3C IgG2a mAb resulted in substantial binding,
whereas 
 
.
 
250 ng of the IgG2a switch variant was required
to show significant binding, with a maximal binding at 1 
 
m
 
g
(Fig. 1). Thus, mouse RBC-binding activity of the 4C8
IgG2a variant was at least 1,000 times less than that of its
IgM isotype and the 34-3C IgG2a mAb. It should also be
mentioned that the staining intensity obtained by the 4C8
IgG2a variant was far lower than that observed with the
4C8 IgM or the 34-3C IgG2a mAb. Marginal RBC-bind-
ing activities by the 4C8 IgG2a variant were confirmed
with a radioimmunoassay (Fig. 2). These results indicated
that the 4C8 mAb has a low binding affinity, while its
binding activity was markedly promoted by the pentameric
high-avidity IgM isotype. Moreover, hemagglutination ac-
tivity was only detectable with the 4C8 IgM mAb, and
neither IgM nor IgG2a 4C8 mAb exhibited complement-
mediated hemolysis in vitro in the presence of guinea pig,
rabbit, or mouse serum (data not shown).
 
Lack of Detection of Opsonized RBCs, but Efficient Elimina-
tion of Circulating RBCs in Mice Injected with the Low-Affinity
4C8 IgG2a Variant.
 
Because of its markedly limited in
vitro binding to mouse RBCs, we determined whether the
4C8 IgG2a variant was capable of binding to circulating
RBCs in vivo. When analyzed by a flow cytometric assay
24, 48, and 72 h after a single intraperitoneal injection of
1 mg of the 4C8 IgG2a variant into BALB/c mice, opsonized
RBCs were undetectable in the circulating blood (Fig. 3 A).
This was in marked contrast to the presence of bound anti-
bodies on essentially all the circulating mouse RBCs be-
tween 24 and 72 h after the administration of 50 
 
m
 
g of
the 4C8 IgM or 34-3C IgG2a mAb. Notably, the staining
pattern obtained by in vitro incubation with the 4C8
IgG2a variant was indistinguishable between RBCs from
mice injected with the 4C8 IgG2a and those from control
mice, excluding a rapid and selective elimination of a sub-
population of circulating RBCs by the low-affinity 4C8
IgG2a (data not shown). Thus, the lack of detection of op-
sonized RBCs in the circulating blood further confirmed a
low-affinity feature of the 4C8 IgG2a switch variant.
Strikingly, mice injected with 1 mg of the 4C8 IgG2a
Figure 1. Flow cytometric analysis of mouse
RBCs stained with different amounts of the 4C8
(IgM and IgG2a) and 34-3C (IgG2a) anti–mouse
RBC mAbs. RBCs freshly prepared from BALB/c
mice were first incubated with different amounts of
various mAbs, and then incubated with biotiny-
lated anti–mouse k chain mAb, followed by PE-
conjugated streptavidin. Shaded histograms indicate
the background staining with anti–mouse k chain
mAb alone. As controls, the results obtained with
isotype-matched control mAbs are shown.
Figure 2. Radioimmunoassay for the detection of anti–mouse RBC
activities by the 4C8 (IgM and IgG2a) and 34-3C (IgG2a) anti–mouse
RBC mAbs. RBCs freshly prepared from BALB/c mice were first incu-
bated with different concentrations of various mAbs, and then incubated
with radiolabeled goat anti–mouse Ig. The results are expressed as the ra-
dioactivity bound to mouse RBCs in the presence of 4C8 IgM (d), 4C8
IgG2a (u), and 34-3C IgG2a (s). As controls, the results obtained with
isotype-matched control mAbs are shown: IgM anti-IgG2a (j) and
IgG2a anti-TNP (n). 
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variant developed a severe anemia with a decrease in Ht
values down to 21% 4 d after the injection (see below). To
verify the elimination of circulating RBCs by the 4C8
IgG2a variant, RBCs were in vivo biotinylated with an in-
travenous injection of NHS-biotin, and their clearance was
then determined after the injection of 1 mg of 4C8 IgG2a
or Hy1.2 IgG2a anti-TNP mAb. As shown in Fig. 3 B, bi-
otinylated RBCs were gradually replaced by newly gener-
ated RBCs in control mice injected with Hy1.2 anti-TNP
mAb, while the injection of the 4C8 IgG2a variant mark-
edly accelerated this process. Although Ht values began to
recover 
 
z
 
5 d after the 4C8 IgG2a mAb injection and re-
turned to almost normal levels by 8 d (Fig. 3 C), the levels
of biotinylated RBCs were further decreased. 8 d after 4C8
IgG2a mAb injection, biotinylated RBCs were hardly de-
tectable (
 
,
 
1%), while 
 
z
 
70% of circulating RBC were still
biotinylated in control mice. This indicated that the 4C8
IgG2a variant indeed bound to circulating RBCs in vivo
and efficiently eliminated them. Notably, the immunoreac-
tivity of biotinylated RBCs, obtained from 24 to 72 h after
in vivo biotinylation, to the 4C8 mAb was comparable to
that of control RBCs, as judged by in vitro and in vivo
binding analyses, and the kinetics and extent of anemia in-
duced by the 4C8 mAb in biotin-treated mice were essen-
tially identical to those of untreated mice (Fig. 3 C and Fig. 4).
 
High Pathogenic Activity of the Low-Affinity 4C8 IgG2a
Variant Promoted through Fc
 
g
 
R-dependent Erythrophagocytosis.
 
To compare the pathogenic activity of the 4C8 IgG2a vari-
ant with its IgM isotype and the high-affinity 34-3C IgG2a
mAb, the development of anemia was analyzed by a single
intraperitoneal injection of various amounts of purified mAb
into BALB/c mice. Despite low-affinity binding to mouse
RBCs, the 4C8 IgG2a mAb was highly pathogenic, and 50
 
m
 
g was sufficient to cause significant anemia (mean Ht val-
ues of five mice 4 d after the injection: 35 
 
6 
 
3%; Fig. 4).
This dose was comparable to that required for the induc-
tion of anemia by its IgM isotype and the high-affinity 34-3C
IgG2a mAb.
Histological examinations showed that erythrophagocy-
tosis by Kupffer cells was the most remarkable pathological
change associated with anemia induced by the 4C8 IgG2a
isotype (Fig. 5 A), as observed in mice developing anemia
after the injection of the 34-3C IgG2a mAb (4). Destruc-
tion of RBCs by phagocytosis was further documented by
extensive iron deposits in Kupffer cells from mice injected
with the 4C8 IgG2a variant (Fig. 5 C). In contrast, the in-
jection of 4C8 IgM mAb at a dose of 250 
 
m
 
g resulted in an
enormous accumulation of agglutinated RBCs in the spleen,
Figure 3. Failure to detect opsonized circulating
RBCs, but development of anemia accompanied
by efficient clearance of circulating RBCs after in-
jection of the 4C8 IgG2a variant in BALB/c mice.
(A) Mouse RBCs were obtained 24 h after an in-
traperitoneal injection of 4C8 IgG2a (1 mg), 4C8
IgM (50 mg), or 34-3C IgG2a (50 mg) anti–mouse
RBC mAb, and then stained with biotinylated
anti–mouse  k chain mAb, followed by PE-conju-
gated streptavidin. Shaded histograms indicate the
background staining with PE-conjugated streptavi-
din. Essentially identical results were obtained with
mouse RBCs obtained 48 and 72 h after injection
of anti–mouse RBC mAb (data not shown). (B and
C) Mouse RBCs were biotinylated in vivo by an
intravenous infusion of NHS-biotin 24 h before
the intraperitoneal injection of 1 mg of purified
4C8 IgG2a (d) or control IgG2a Hy1.2 anti-TNP
mAb (s) on day 0. The clearance of biotinylated
RBCs was followed by the staining with streptavi-
din Red 670. Results are expressed as percent bi-
otinylated RBCs (Biotin-RBC) of three individual
mice, measured 2, 4, and 8 d after the mAb injec-
tion (B). The development of anemia was deter-
mined by measuring Ht values (C).
Figure 4. Development of anemia
by the 4C8 and 34-3C anti–mouse
RBC mAbs in BALB/c mice. Mice
were intraperitoneally injected with
different amounts of purified mAbs on
day 0: 25 mg, 50 mg, 200 mg, or 1 mg
of 4C8 IgG2a mAb; 25, 50, 100, or
250 mg of 4C8 IgM mAb; 12.5, 25,
50, or 100 mg of 34-3C IgG2a mAb.
Results are expressed as mean Ht
values of three to five mice. 
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and in hepatic sinusoids accompanied by occasional necro-
sis of hepatic parenchymal cells (Fig. 5 B), as shown previ-
ously (4).
To determine the contribution of Fc
 
g
 
R-mediated
erythrophagocytosis to the pathogenesis of the 4C8 IgG2a–
induced anemia, the development of anemia was assessed in
FcR
 
g
 
-deficient mice lacking functional expression of both
Fc
 
g
 
RI and FcgRIII involved in phagocytosis of IgG2a-
opsonized RBCs (13, 14). As shown in Fig. 6, FcRg-defi-
cient mice were completely resistant to the pathogenic ef-
fect of 1 mg of the 4C8 IgG2a mAb, and failed to exhibit
erythrophagocytosis, as documented by the lack of iron de-
posits in their Kupffer cells (Fig. 5 D).
Discussion
In this study, we have demonstrated that the 4C8 anti–
mouse RBC autoantibody, derived from lupus-prone NZB
mice, has a low binding affinity to its corresponding self-
antigen, yet its IgM and IgG2a isotypes exhibit a remark-
ably high pathogenic potency. Our results indicate that the
pentameric form of a low-affinity IgM isotype, by promot-
ing the binding and agglutination of RBCs, is critical for its
pathogenic activity, and that the capacity of the IgG2a iso-
type to interact with FcgR involved in erythrophagocyto-
sis is responsible, despite its barely detectable RBC-binding
activity, for its hemolytic activity. Demonstration of the high
pathogenic potency of low-affinity autoantibodies high-
lights a remarkable role of Ig heavy chain effector functions,
as opposed to a relatively minor role of autoantigen-binding
affinities, in the pathogenesis of autoimmune hemolytic
anemia.
A striking feature of our analysis is that despite the lack
of detection of significantly opsonized RBCs in the circu-
Figure 5. (A) Representative
histological appearance of liver 4 d
after the injection of 1 mg of the
4C8 IgG2a variant. Note the pres-
ence of marked erythrophagocy-
tosis by Kupffer cells (HE; original
magnification: 3400). (B) Repre-
sentative histological appearance
of liver from BALB/c mice that
died of anemia 2 d after the in-
jection of 250 mg of the 4C8 IgM
mAb. Note an enormous accu-
mulation of agglutinated RBCs in
sinusoids of liver accompanied by
necrosis of hepatic parenchymal
cells (HE; original magnification:
3100). (C and D) Representative
histological appearance of iron
deposits in Kupffer cells from
BALB/c and FcRg-deficient mice
after the injection of 1 mg of the
4C8 IgG2a variant. Mice injected
with the 4C8 IgG2a variant were
killed at day 7. The extent of in
vivo RBC destruction by phago-
cytosis was revealed by coloration
of liver sections with Perls iron
staining. Note extensive iron de-
posits in Kupffer cells from
BALB/c  mice injected with the
4C8 IgG2a mAb (C), in marked
contrast to the complete absence
of iron deposits in livers from
FcRg-deficient mice injected with
the 4C8 IgG2a mAb (D) (original
magnification: 3200).
Figure 6. Development of anemia in FcRg-deficient (d) and wild-
type (s) mice after the injection of 1 mg of the 4C8 IgG2a variant. Mean
Ht values (6 1 SD) of three mice are shown.1694 Pathogenicity of Low-Affinity Autoantibodies
lating blood, the 4C8 IgG2a variant with low binding af-
finity is able to induce a severe anemia as a result of periph-
eral destruction of circulating RBCs. This was documented
by an efficient clearance of in vivo–biotinylated circulating
RBCs and by Kupffer cell–mediated erythrophagocytosis.
To our surprise, the amount of the IgG2a isotype-switch
variant required to induce anemia was comparable to that
of the high-avidity IgM isotype exhibiting .1,000 times
stronger RBC-binding activity. This indicates that the
pathogenic activity of low-affinity IgG anti-RBC autoanti-
bodies is dramatically enhanced when provided with an
appropriate Ig heavy chain effector function, namely the
capacity to interact with FcgR involved in erythrophago-
cytosis. Thus, a rapid FcgR-mediated uptake by Kupffer cells
of even very poorly opsonized RBCs present in hepatic
microcirculation appears to be an extremely efficient mecha-
nism for the development of anemia induced by IgG anti-
RBC autoantibodies.
An additional, unexpected observation was that the
pathogenic potential of the low-affinity 4C8 IgG2a autoan-
tibody was also comparable to the high-affinity 34-3C
IgG2a mAb (4). However, this comparison is only tentative
in its interpretation because of possible differences in the
specificity of the 4C8 and 34-3C mAbs (24). Only experi-
ments comparing IgG2a mAbs of the same specificity, but
with different affinities, would provide definitive conclu-
sions on this issue. Nevertheless, our results strongly suggest
that RBC-binding affinities of Coombs’ autoantibodies ap-
parently play a relatively minor role for in vivo hemolytic
activities of the IgG2a isotype capable of interacting effi-
ciently with two different classes of FcgR (FcgRI and
FcgRIII) involved in erythrophagocytosis (13, 14, 25, 26).
It may be worth noting that although the pathogenicity of
the 4C8 and 34-3C IgG2a mAbs was almost comparable at
lower doses, it appears that the 34-3C mAb at higher doses
is more pathogenic than the 4C8 IgG2a (Fig. 4). Although
we do not have a straightforward explanation for this phe-
nomenon at present, it can be speculated that the IgG2a
isotype of anti-RBC autoantibodies could mediate ery-
throphagocytosis through their binding to the high-affinity
FcgRI, followed by their subsequent interaction with cir-
culating RBCs. A significant binding of free IgG2a anti-
RBC to FcgRI on phagocytic cells is likely to occur only
when higher doses of IgG2a mAb are injected, because of
the competition of circulating monomeric IgG2a without
anti-RBC activity. Owing to its high-affinity RBC-bind-
ing capacity, even limited amounts of the cell-bound 34-3C
IgG2a may efficiently capture circulating RBCs, thereby
mediating erythrophagocytosis. In contrast, the ability to
capture circulating RBCs by the low-affinity 4C8 IgG2a
bound on Kupffer cells may be too poor to cause erythro-
phagocytosis by such a mechanism. Consistent with this
hypothesis, our recent analysis on different FcgR-deficient
mice has shown that the erythrophagocytosis caused by
lower doses of the 34-3C and 4C8 IgG2a mAbs is primarily
mediated by the low-affinity FcgRIII, while FcgRI is only
involved in the development of anemia induced by higher
doses of these mAbs (our unpublished results).
In addition to the remarkable contribution of IgG Fc re-
gion mediating FcgR interaction to pathogenic activities of
the low-affinity 4C8 IgG2a variant, these studies also sug-
gest that the strong pathogenic activity of the IgM 4C8 iso-
type is dependent on its pentameric form, which promotes
the binding and agglutination of RBCs. Consequently, the
IgM isotype of the 4C8 mAb induces a different form of
severe anemia, resulting from massive agglutination of RBCs
in spleen and liver, which does not involve FcgR-medi-
ated phagocytosis and complement activation (4, 13). Al-
though the present study does not formally prove that the
pentameric form of the 4C8 IgM antibody is crucial for the
in vivo agglutination of RBCs, we have recently observed
that the IgG3 variant of the 4C8 mAb exhibits neither
FcgR-dependent erythrophagocytosis nor agglutination of
RBCs in vivo (our unpublished results), supporting the im-
portance of the IgM pentameric form for the in vivo agglu-
tination of RBCs by this mAb. However, it should be
stressed that we have previously observed that two of four
IgM anti-RBC mAbs failed to induce anemia (4). The lack
of pathogenic activities by these two IgM autoantibodies is
likely to be related to their specificities, since they are un-
able to induce agglutination of mouse RBCs in vitro. Thus,
the surface density of corresponding self-antigen epitopes
may be too low to promote high-avidity binding and ag-
glutination of mouse RBCs in vivo by these IgM anti-RBC
autoantibodies.
Our demonstration here of the high pathogenic potency
of low-affinity autoantibodies suggests that the affinity mat-
uration of autoantibodies may not be a critical process for
the generation of autoantibodies with immunopathologic
consequences. This is consistent with the demonstration that
low-affinity anti-IgG2a rheumatoid factors of the IgG3 iso-
type are able to induce remarkable pathology—immune
complex–mediated skin vasculitis and lupus-like glomeru-
lonephritis—owing to their cryoglobulin activity, a unique
property of the IgG3 isotype (11, 12). These results provide
new insight into the cellular basis for the generation of
pathogenic autoantibodies of IgM and IgG isotypes. It has
already been shown that a fraction of B cells expressing the
low-affinity 4C8 autoantibody can escape clonal deletion in
the bone marrow and can be activated to produce patho-
genic autoantibodies in the periphery, as a result of nonspe-
cific activation of B cells (27, 28). These autoantibodies may
even be switched to IgG classes under certain conditions,
possibly through the action of the cytokines, independently
of the presence of autoantigen-specific T helper cells, as is
the case of T cell–independent type II immune responses
(29). Genetic abnormalities present in certain autoimmune-
prone mice may favor the switching of IgM to IgG isotypes,
as shown by a spontaneous class switch from IgM to IgG2a
autoantibody by B cells derived from lupus-prone (NZB 3
NZW)F1 mice in the absence of functional CD41 T helper
cells (30, 31). In addition, we have recently observed that
the constitutive expression of the bcl-2 transgene in germi-
nal center B cells is able to induce the spontaneous produc-
tion of IgG autoantibodies (our unpublished results). There-
fore, it is possible that autoreactive B cells can be generated1695 Fossati-Jimack et al.
as a result of somatic hypermutations in the germinal cen-
ters during immune responses against environmental antigens,
and such B cells may persist, if they are defective in the
process of apoptosis, which is likely to be one of the genetic
defects present in autoimmune-prone mice (32, 33). Thus,
although the presence of somatic mutations in Ig variable
regions, including CDR, of autoantibodies is likely to be
CD41 T cell dependent, several autoantibody-producing B
cells may not have been driven by autoreactive T helper
cells and self-antigens. This idea is consistent with a limited
affinity maturation of clonally related rheumatoid factors,
despite extensive somatic mutations, derived from a Fas-
deficient MRL-lpr/lpr mouse (10). Clearly, in view of the
high pathogenic potential of low-affinity autoantibodies
and of the critical role of CD41 T cells in the development
of autoimmune diseases (34), better understanding of the
nature of help provided by CD41 T cells would help eluci-
date the cellular basis central to the development of autoan-
tibody-mediated autoimmune diseases.
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